01 October 2005
Cost effectiveness of positron emission tomography in Canada.
J Scott Sloka, Peter D HollettMed Sci Monit 2005; 11(10): PH1-6 :: ID: 430329
Abstract
BACKGROUND: Positron emission tomography (PET) has been shown to be costeffective for the staging of stage I and II breast cancer, recurrent colorectal cancer and non smallcell lung cancer. This study determines a required catchment size for the management of these three cancersbased on a breakeven analysis. MATERIAL/METHODS: Cost effectiveness analysis is used to determine thecost savings of introducing PET into the diagnostic algorithm for the staging of stage I and II breastcancer, recurrent colorectal cancer and non small cell lung cancer. The cost savings for these cancersare used to calculate a required catchment area for the installation of a PET center with cyclotron.RESULTS: The aggregate estimated "breakeven" cost of a PET study would be dollars 2195, well below theexpected cost per study. In order to break even, each PET device would require 740 new cases per year.For a general representative population, one person per 766 may benefit from a PET scan if a PET studywas included in the diagnostic algorithm for all three cancers. Finally, a calculated catchment sizeof 567,000 people would support the use of a PET center with cyclotron CONCLUSIONS: The use of PET forthe staging of cancer appears to be cost effective in most jurisdictions in Canada.
Keywords: Canada, Breast Neoplasms - radionuclide imaging, Carcinoma, Non-Small-Cell Lung - radionuclide imaging, Colorectal Neoplasms - radionuclide imaging, Cost-Benefit Analysis, Lung Neoplasms - radionuclide imaging, Neoplasm Staging, Positron-Emission Tomography - economics
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
In Press
27 Jun 2022 : Clinical Research
Automatic Identification of Depression Using Facial Images with Deep Convolutional Neural NetworkMed Sci Monit In Press; DOI: 10.12659/MSM.936409
23 Jun 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical Research
A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...Med Sci Monit In Press; DOI: 10.12659/MSM.937316
21 Jun 2022 : Clinical Research
Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.937016
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952